Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL)

被引:33
|
作者
Perea, G
Altés, A
Bellido, M
Aventín, A
Bordes, R
Ayats, R
Remacha, AF
Espinosa, I
Briones, J
Sierra, J
Nomdedéu, JF
机构
[1] Hosp Santa Cruz & San Pablo, Dept Haematol, E-08025 Barcelona, Spain
[2] Hosp Santa Cruz & San Pablo, Dept Pathol, E-08025 Barcelona, Spain
关键词
bone marrow; flow cytometry; follicular lymphoma; prognosis;
D O I
10.1111/j.1365-2559.2004.01937.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aim: To determine the efficacy of flow cytometry (FC) in the assessment of bone marrow (BM) in B-cell non-Hodgkin lymphoma (B-NHL). FC is a common practice, but is far from being validated. Methods and results: Morphological analysis and FC immunophenotyping were perfomed on 421 samples. T-cell lymphomas, Hodgkin's disease, chronic lymphocytic leukaemia and hairy cell leukaemia were not included in the study. Clonality was assessed by the standard kappa/lambda/CD19 test. Aberrant immunophenotypes present in the B-cell subpopulation were also investigated. A double-step procedure was employed in all cases to increase the sensitivity of the FC procedure. Of 380 evaluable samples, 188 corresponded to follicular lymphoma (FL), 58 to diffuse large B-cell lymphoma (DLBCL), 57 to mantle cell lymphoma (MCL), seven to Burkitt's lymphoma and the remaining 70 samples to other low-grade lymphomas. Morphological marrow infiltration was found in 148 cases, and flow immunophenotyping identified 138 cases with BM involvement. A concordance between the two methods was detected in 298 cases (79%). There was a discordance in 82 cases (21%): morphology positive/FC negative in 46 cases and morphology negative/FC positive in 36 (61% of all cases with discordance were from FL). There was no difference in outcome when patients with discordances were compared with patients without discordances. Conclusions: Most samples showed concordance between morphological and FC results. FC identified BM involvement in the absence of morphological infiltration. Morphology/FC discordance seems to have no influence on the outcome of FL patients.
引用
收藏
页码:268 / 274
页数:7
相关论文
共 50 条
  • [41] Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry
    Ohmoto, Akihiro
    Maeshima, Akiko Miyagi
    Taniguchi, Hirokazu
    Tanioka, Kensaku
    Makita, Shinichi
    Kitahara, Hideaki
    Fukuhara, Suguru
    Munakata, Wataru
    Suzuki, Tatsuya
    Maruyama, Dai
    Kobayashi, Yukio
    Tobinai, Kensei
    LEUKEMIA & LYMPHOMA, 2015, 56 (12) : 3301 - 3305
  • [42] Phase II study of denileukin diftitox (ONTAK®) in patients with relapsed/refractory B-cell Non-Hodgkin's lymphoma (B-NHL) and poor bone marrow reserve.
    Czuczman, Myron S.
    Pinter-Brown, Lauren
    Lechowicz, Mary Jo
    Bartlett, Nancy
    Lazarus, Hillard
    Lister, John
    Goy, Andre
    Kahanic, Stephen
    Rosen, Peter
    Acosta, Mark
    BLOOD, 2006, 108 (11) : 263B - 264B
  • [43] Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas
    Ren, Yongsheng
    Akyurek, Nalan
    Schlette, Ellen
    Rassidakis, Georgios Z.
    Medeiros, L. Jeffrey
    HUMAN PATHOLOGY, 2006, 37 (11) : 1407 - 1413
  • [44] Targeting Asparagine and Serine Metabolism in Germinal Centre-Derived B Cells Non-Hodgkin Lymphomas (B-NHL)
    Eraslan, Zuhal
    Papatzikas, Grigorios
    Cazier, Jean-Baptiste
    Khanim, Farhat L.
    Guenther, Ulrich L.
    CELLS, 2021, 10 (10)
  • [45] Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas
    Palacio, C
    Acebedo, G
    Navarrete, M
    Ruiz-Marcellán, C
    Sanchez, C
    Blanco, A
    López, A
    HAEMATOLOGICA, 2001, 86 (09) : 934 - 940
  • [46] Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin lymphomas and Hodgkin lymphomas
    Ren, Y
    Akyurek, N
    Rassidakis, GZ
    Medeiros, LJ
    LABORATORY INVESTIGATION, 2006, 86 : 243A - 243A
  • [47] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin lymphomas and Hodgkin lymphomas
    Ren, Y
    Akyurek, N
    Rassidakis, GZ
    Medeiros, LJ
    MODERN PATHOLOGY, 2006, 19 : 243A - 243A
  • [49] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [50] Monoclonal gammopathies in B-cell non-Hodgkin's lymphomas
    Economopoulos, T
    Papageorgiou, S
    Pappa, V
    Papageorgiou, E
    Valsami, S
    Kalantzis, D
    Xiros, N
    Dervenoulas, J
    Raptis, S
    LEUKEMIA RESEARCH, 2003, 27 (06) : 505 - 508